Invitrall

1 known investors

Invitrall develops long-lasting, disease-representative human skin organoids from reprogrammed human cells, combining cell reprogramming, organoids, and machine learning to create human preclinical models. Its platform supports efficacy and repeated-dose toxicity testing for pharmaceutical and dermocosmetics companies developing skin drugs and cosmetics, as an alternative to animal testing.

AI & Machine LearningBiotechHealthtech